Clinical trial
Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of…
NCT00080002 · Enzon Pharmaceuticals, Inc., Industry · Terminated
Key facts
| NCT number | NCT00080002 |
|---|---|
| Title | Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction |
| Official title | Effectiveness and Safety Study of Pegamotecan (PEG-Camptothecin) in Patients With Locally Advanced or Metastatic Cancer of the Stomach or Gastroesophageal Junction Who Have Relapsed or Progressed Following a Previous Chemotherapy Treatment |
| Lead sponsor | Enzon Pharmaceuticals, Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer of Stomach, Gastroesophageal Cancer |
| Intervention type | Drug |
| Interventions | Pegamotecan |
| Start date | Dec 1, 2003 |
| First posted | Mar 23, 2004 |
| Last update posted | Sep 6, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: